Beta Drugs Ltd

Beta Drugs Ltd – Leading the Oncology Pharma Revolution 🌏💊

🏢 Company Overview

Beta Drugs Ltd is a prominent name in India’s oncology (anti-cancer) drug market, offering an extensive portfolio of oncology solutions with a mission to make life-saving treatments accessible and affordable. Ranked in the Top 10 oncology firms in India, Beta Drugs has built a reputation for quality, innovation, and rapid growth.

🌐 Market Position & Partnerships

Top 10 in Indian oncology with 100+ SKUs
Global Reach: Presence in 15+ countries and 50+ registered products
Trusted Partner: Contract manufacturing for 49+ companies, including Zydus, Cadila, Alkem, and Torrent

📈 Financial Highlights

Market Cap: ₹1,846 Cr | Current Price: ₹1,920 | P/E Ratio: 50.6x
4-Year Sales & PAT CAGR: 38% 📈
ROE: 25% | ROCE: 32.8%
Debt-to-Equity: 0.25x
PAT Margin: 12-13%

Outlook: Targeting 30% revenue growth in coming years with consistent PAT margins.

Here’s a clean, attractive website outline for Beta Drugs Ltd, optimized for readability and highlighting its unique points:

Beta Drugs Ltd – Leading the Oncology Pharma Revolution 🌏💊

🏢 Company Overview

🌐 Market Position & Partnerships

Top 10 in Indian oncology with 100+ SKUs
Global Reach: Presence in 15+ countries and 50+ registered products
Trusted Partner: Contract manufacturing for 49+ companies, including Zydus, Cadila, Alkem, and Torrent

📈 Financial Highlights

Market Cap: ₹1,846 Cr | Current Price: ₹1,920 | P/E Ratio: 50.6x
4-Year Sales & PAT CAGR: 38% 📈
ROE: 25% | ROCE: 32.8%
Debt-to-Equity: 0.25x
PAT Margin: 12-13%

Outlook: Targeting 30% revenue growth in coming years with consistent PAT margins.

🚀 Key Growth Segments

CDMO (48%): Manufacturing for companies like Glenmark and Torrent
Domestic Brands (29%): Cancer treatments under brands like Canrib and Adcilib
International (16%): Expanding with over 350 products in pipeline
API (7%): Producing key ingredients for cancer drugs, e.g., Azacitidine, Abiraterone

🔹 Recent Developments & Achievements

Increased Share Capital: From ₹10 Cr to ₹10.5 Cr
Strategic Funding: Raised ₹117 Cr in CCDs and equity preferential
Forbes Asia “Best Under a Billion” Award 2024: Earned for the 3rd consecutive year, underscoring growth in oncology and international reach
EuGMP Certification Plans: Regulatory strides for expansion in Europe

🌍 Future Outlook & Innovation

With plans to launch 25 new oncology products by 2026, Beta Drugs is strengthening its R&D and production capabilities to meet rising demand for affordable cancer treatments. As Merck’s Keytruda patent nears expiration, Beta Drugs is poised to introduce affordable alternatives, making advanced therapies accessible to more patients in India and abroad.

💼 Promoter & Institutional Support

Promoter Holding: 66.7% with zero pledge
Notable Investors: Ashish Kacholia holds a 5.78% stake, endorsing the company’s potential in the oncology sector

Why Invest in Beta Drugs?